Loncar Cancer Immunotherapy ETF (CNCR)

$10.96 0.01 (0.09%)

16:15 EDT CNCR Stock Quote Delayed 30 Minutes

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

7 ETFs for the End of the Coronavirus

5 Strong Healthcare ETFs to Buy

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 1,771

Day's Range $10.90 - $11.05

52-Week Range $10.90 - $15.82

Dividend & Yield N/A (N/A)

CNCR Stock Predictions, Articles, and Loncar Cancer Immunotherapy ETF News

From InvestorPlace
From the Web

5 Biotech ETFs for Outsized Gains

By Todd Shriber, InvestorPlace Contributor Apr 25, 2018

Data support the notion that biotechnology stocks offer outperformance potential over diversified healthcare benchmarks. And these 5 biotech ETFs are a great to play the space.

The 10 Best ETFs of February 2018

By Robert Waldo, InvestorPlace Senior Web Editor Feb 28, 2018

The tides have shifted, somewhat, since January and some of the best ETFs of February focus on unfamiliar spaces, while other ETFs maintained their general outperformance over the S&P 500.

4 Market-Beating Sector ETFs and Stocks

By Zacks Investment Research Feb 28, 2018

A few sectors have easily survived the market rout and are crushing the broad market this month. Compare Brokers...

The 10 Best ETFs of January 2018

By Robert Waldo, InvestorPlace Senior Web Editor Feb 2, 2018

These were the some of the best ETFs in January. Each outperformed the S&P 500 by at least 5% or more. Here's what investors need to know about each ETF.

5 Secret Santa ETFs and Stocks to Buy Ahead of Christmas

By Zacks Investment Research Dec 18, 2017

While most of the stocks and ETFs have been surging over the past one month, there are some hidden gems that could surprise investors with big returns this Chri...

3 Healthcare ETFs That Will Bounce Back in 2017

By Todd Shriber, InvestorPlace Contributor Dec 13, 2016

2016 was a bad year for healthcare ETFs, but with the presidential election behind us, ETFs like IHI, CNCR and PTH could see a surge.

3 Promising Oncology Stocks To Consider Adding To Your Portfolio

From Talk Markets Jun 14, 2021

With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.

4 Promising Oncology Stocks to Consider Adding to Your Portfolio

From StockNews.com Jun 11, 2021

The Biotech industry has been working to develop cancer treatments for a long time. But now, with tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca (AZN), Amgen (AMGN), Incyte (INCY), and Champions Oncology (CSBR) are valuable additions to one’s portfolio now. So, let’s examine these companies more closely.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

From Talk Markets Apr 30, 2021

2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space.

Sector Watch: More oncology events as cancer ETF breaks out (NASDAQ:CNCR)

From Seeking Alpha Sep 20, 2020

Health Care, and more specifically oncology, will continue to gain attention with the events on the calendar this week.The Sachs 20th Annual Biotech in Europe Forum runs from Monday to Thursday. Monday, morning, Amgen (NASDAQ:AMGN) will present results from a Phase 1 Study of AMG 160 for prostate cancer as part of the European Society of Medical Oncology Virtual Congress.And Tuesday morning, Merck, whose oncology division has outperformed competitors over the last few years, is hosting an Oncology Virtual IR Briefing as part of ESMO 2020, according to Seeking Alpha's Catalyst Watch.A wave of deals in the cancer-treatment space has sparked sharp rallies across biotech. The big trigger last week was Gilead Sciences (NASDAQ:GILD) agreeing to acquire Immunomedics (NASDAQ:IMMU) in a transaction that values Immunomedics at ~$21B, giving Gilead Trodelvy, used to treat certain forms of breast cancer and being evaluated for a number of other cancers.On Friday, Piper Sandler issued a list of biotechs that could be in the sights of acquirers for their oncology treatment.

6 Sector ETFs Surviving the Market Rout

From Talk Markets Sep 15, 2020

Amid the uncertainties, a few sectors have survived last week’s turmoil. Here are six of that could be compelling picks for the weeks ahead as long as volatility persists.

5 ETFs Jump After Three-Day Rout: Will The Rally Last?

From Talk Markets Sep 10, 2020

Here are the ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.